| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers I > Headlines for Icagen, Inc. > News item |
Icagen begins pediatric study of ICA-17043 for sickle cell disease
By Angela McDaniels
Seattle, May 31 - Icagen Inc. has begun an open-label, parallel group trial of ICA-17043 in 28 patients aged six to 16 with sickle cell disease at eight academic medical centers in the United States, according to a company news release.
The company said the objective of the study is to evaluate the pharmacokinetics, pharmacodynamics and tolerability of ICA-17043 in pediatric patients with sickle cell disease.
The drug is taken orally and is being developed for once-a-day dosing. Patients will receive study medication according to one of three dosing schedules over a period of 21 days.
The study data will be used to select doses for subsequent clinical evaluations of the safety and efficacy of ICA-17043 in pediatric subjects.
Sickle cell disease is a chronic and debilitating genetic blood disorder that affects about 100,000 patients in the United States who suffer a variety of disease complications and a shortened lifespan, according to the release.
ICA-17043 is a novel small molecule ion channel inhibitor that targets a particular potassium channel, called the Gardos channel, which is located on the membrane of red blood cells. The drug received both fast track designation and orphan drug designation from the Food and Drug Administration, the company said.
Icagen also said it is conducting a pivotal phase 3 clinical trial of ICA-17043 in collaboration with the McNeil Pediatrics Division of McNeil-PPC Inc.
Icagen is a biopharmaceutical company based in Research Triangle Park, N.C., that develops novel, orally administered small molecule drugs that modulate ion channel targets.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.